Support Line: 0800 002 9002
General Enquiries: 01223 870008

Donate

News Archive

Month: October 2023

Highest risk patients with RCC benefit from adjuvant everolimus

Highest risk patients with RCC benefit from adjuvant everolimus

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell ...
Dovitinib Companion Diagnostic Shows Results in RCC

Dovitinib Companion Diagnostic Shows Results in RCC

Dovitinib
The drug response predictor companion diagnostic for dovinitib (DRP-Dovitinib) demonstrates potential to identify ...
No results found.